Humasis Co. Ltd (205470) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humasis Co. Ltd (205470) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.98 Billion ≈ $6.08 Million USD) by net assets (₩248.94 Billion ≈ $168.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Humasis Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Humasis Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Humasis Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humasis Co. Ltd ranked by their cash flow conversion efficiency. Explore 205470 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Piedmont Lithium Inc
AU:PLL
|
-0.008x |
|
Lealea Enterprise Co Ltd
TW:1444
|
0.003x |
|
104 Corporation
TW:3130
|
0.026x |
|
Profound Medical Corp
TO:PRN
|
-0.222x |
|
Yesco Holdings Co. Ltd
KO:015360
|
0.182x |
|
Solar A/S
CO:SOLAR-B
|
0.215x |
|
Smart Parking Ltd
AU:SPZ
|
0.132x |
|
Spok Holdings Inc
NASDAQ:SPOK
|
0.017x |
Annual Cash Flow Conversion Efficiency for Humasis Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Humasis Co. Ltd from 2016 to 2024. View today's stock price for Humasis Co. Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩229.26 Billion ≈ $155.37 Million |
₩30.37 Billion ≈ $20.58 Million |
0.132x | +168.60% |
| 2023-12-31 | ₩287.33 Billion ≈ $194.72 Million |
₩-55.48 Billion ≈ $-37.60 Million |
-0.193x | -133.05% |
| 2022-12-31 | ₩346.73 Billion ≈ $234.98 Million |
₩202.60 Billion ≈ $137.30 Million |
0.584x | -42.43% |
| 2021-12-31 | ₩202.01 Billion ≈ $136.90 Million |
₩205.02 Billion ≈ $138.94 Million |
1.015x | +246.69% |
| 2020-12-31 | ₩48.84 Billion ≈ $33.10 Million |
₩14.30 Billion ≈ $9.69 Million |
0.293x | +472.45% |
| 2019-12-31 | ₩15.24 Billion ≈ $10.33 Million |
₩779.58 Million ≈ $528.31K |
0.051x | +210.38% |
| 2018-12-31 | ₩16.13 Billion ≈ $10.93 Million |
₩-747.08 Million ≈ $-506.29K |
-0.046x | +75.66% |
| 2017-12-31 | ₩15.60 Billion ≈ $10.57 Million |
₩-2.97 Billion ≈ $-2.01 Million |
-0.190x | -1468.41% |
| 2016-12-31 | ₩10.86 Billion ≈ $7.36 Million |
₩151.11 Million ≈ $102.40K |
0.014x | -- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more